Cellosaurus SUP-M2 (CVCL_2209)

Cell line name SUP-M2
Synonyms SUPM2
Accession CVCL_2209
Resource Identification Initiative To cite this cell line use: SUP-M2 (RRID:CVCL_2209)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Doubling time: ~40-50 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Cerebrospinal fluid.
Disease Anaplastic large cell lymphoma (NCIt: C3720)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_V405 (SUP-M2-CR03); CVCL_B228 (Sup-M2-TS)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ

Markers:
AmelogeninX
CSF1PO11,12
D13S31710,11
D16S53911,12
D5S81811
D7S8208,12
TH018,9.3
TPOX8,10
vWA16,18
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=2525056
Morgan R., Smith S.D., Hecht B.K., Christy V., Mellentin J.D., Warnke R., Cleary M.L.
Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis.
Blood 73:2155-2164(1989)

PubMed=15356658; DOI=10.1038/sj.leu.2403465
Drexler H.G., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma.
Leukemia 18:1569-1571(2004)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections DSMZ; ACC-509
Cell line databases/resources CCLE; SUPM2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 1331040
GDSC; 1331040
LINCS_LDP; LCL-1919
Ontologies BTO; BTO:0004775
Biological sample resources BioSample; SAMN03473512
Gene expression databases GEO; GSM887660
GEO; GSM888752
GEO; GSM1670493
Polymorphism and mutation databases Cosmic; 1086004
Cosmic; 1152615
Cosmic; 1995648